Sponsors (5)
The bill would speed patient access to potentially lifesaving therapies and encourage domestic research by relying on trusted foreign approvals and strict 30‑day timelines, but does so at the cost of increased safety, oversight, equity, and cost risks if foreign standards or the compressed review process prove inadequate.
Patients with serious or immediately life‑threatening conditions can get faster access to drugs, biologics, and clinical trials by allowing U.S. reliance on authorizations from trusted foreign regulators.
FDA decision and review timelines are shortened (30‑day determinations and labeling/postmarket finalization), accelerating availability of therapies to U.S. providers and patients.
The bill preserves a U.S. safety backstop by allowing withdrawal or suspension of approvals if new evidence shows unreasonable risk, maintaining some domestic oversight.
U.S. patients and health systems face increased safety risks if foreign regulatory standards or oversight differ from FDA practices, potentially exposing Americans to less‑vetted products.
Rapid 30‑day approval windows and reliance on foreign reviews raise the risk of post‑market withdrawals or approvals based on data that may not reflect U.S. populations, disrupting care and undermining treatment continuity.
Faster market entry and treating requests as user‑fee applications could increase spending on new treatments and lead sponsors to pass higher costs to consumers, insurers, and taxpayers.
Based on analysis of 4 sections of legislative text.
Creates FDA pathways to accept certain trusted foreign regulator authorizations for marketing and U.S. clinical‑trial allowances for products treating immediately life‑threatening conditions, with 30‑day decision deadlines.
Official title: To accelerate patient access to innovative medicines and clinical trials for life-threatening diseases by establishing a reciprocal approval mechanism with trusted international regulatory authorities.
Introduced March 17, 2026 by Pete Sessions · Last progress March 17, 2026
Creates a new FDA pathway that lets certain drugs, biologics, and medical devices for immediately life‑threatening conditions be marketed in the U.S. based on prior lawful authorization by specified “trusted international regulatory authorities.” Sponsors can request a reciprocal marketing approval or a reciprocal allowance to run the same clinical trial in the U.S.; the Secretary must act within 30 days, may require labeling and postmarket studies, and may suspend or withdraw approvals for safety reasons. The bill aims to speed patient access to innovative therapies and encourage clinical research in the U.S. by recognizing select foreign regulatory decisions.